Insight Molecular Diagnostics Inc. (IMDX)

IMDX Diagnostics

BiotechSign Signal Grade

F
Signal Grade
10.4/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
55
Clinical Activity
0
Short Interest
30

Pipeline Overview

Therapeutic Focus
Diagnosticssrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
7.9 months
Cash Runway Estimate
55/100
Dilution Score
573,249
Outstanding Warrants
15Warrant Risk
40Convertible Risk
60Offering Ability

Dilution score: 55/100 (HIGH), 7.9 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

9.84%
Float Shorted
4.8
Days to Cover
MODERATE
Squeeze Risk
+6.6%
SI Change
INCREASING
Trend
992,474
Shares Short

Short interest: 9.84% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Insight Molecular Diagnostics Inc..

Full IMDX Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.